Novanta is trading 5% up at $172.36 as investors react to its August 5 second-quarter results and upgraded outlook. - Revenue was $265.8 million and adjusted EPS $0.89; 2026 revenue guidance rose to $1.13 billion-$1.14 billion. - The outlook includes Riverpoint Medical, expected to be immediately accretive to revenue, margins, and earnings. - Closed at $163.86 on August 10 after strong sessions since July 31; broader markets were essentially flat, making company-specific earnings momentum the clearest catalyst.